Mesoblast (MESO) Common Equity (2015 - 2025)

Mesoblast has disclosed Common Equity across 11 years of filings, most recently posting $574.7 million for Q4 2025.

• Common Equity for Q4 2025 came in at $574.7 million, up 24.59% year-over-year; the trailing twelve-month figure through Dec 2025 was $574.7 million (up 24.59% YoY), and the FY2025 annual result was $597.4 million, up 24.38% from the prior year.
• Common Equity came in at $574.7 million for Q4 2025 at Mesoblast, down from $597.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $600.9 million in Q1 2021 to a low of $461.3 million in Q4 2024.
• The 5-year median for Common Equity is $517.1 million (2022), against an average of $528.1 million.
• Across the five-year window, Common Equity fell 14.51% in 2022 and rose 24.59% in 2025, its largest moves.
• Mesoblast's Common Equity stood at $535.5 million in 2021, then fell by 6.63% to $500.0 million in 2022, then advanced by 1.75% to $508.7 million in 2023, then dropped by 9.33% to $461.3 million in 2024, then grew by 24.59% to $574.7 million in 2025.
• The last three Common Equity figures came in at $574.7 million (Q4 2025), $597.4 million (Q2 2025), and $461.3 million (Q4 2024), per Business Quant data.